Glucopet (Fludeoxyglucose (18f))

Glucopet is a radiopharmaceutical containing the active ingredient fludeoxyglucose (18F) supplied as a sterile solution for injection. It is a prescription‑only product marketed in the European Union and is used in positron emission tomography (PET) imaging to assess metabolic activity in various tissues. The compound combines a glucose analog with the positron‑emitting radionuclide fluorine‑18, enabling visualization of cellular processes in clinical diagnostics applications.

Glucopet is employed as a diagnostic agent in PET scans that evaluate tissue metabolism across several clinical specialties.

- Oncologic PET imaging for detection, staging, and monitoring of malignant tumors. - Cardiac PET imaging to assess myocardial perfusion and viability. - Neurologic PET imaging for investigation of epilepsy, dementia, and brain metabolism. - Evaluation of therapeutic response in cancer patients undergoing treatment. - Research use in metabolic studies and drug development trials.

Adverse reactions to Glucopet are generally mild and transient, but rare serious events have been reported.

Common: - Mild nausea or vomiting shortly after injection. - Temporary flushing or warmth sensation at the injection site. - Short‑lasting headache or dizziness.

Serious: - Severe allergic reaction such as anaphylaxis. - Acute hypotension or cardiovascular collapse. - Persistent vomiting or severe gastrointestinal upset requiring medical attention.

Glucopet should be administered by qualified personnel in facilities equipped for radiopharmaceutical handling.

- Verify patient identity and indication before injection. - Assess for known hypersensitivity to fluorodeoxyglucose or similar compounds. - Use appropriate radiation safety measures to protect staff and other patients. - Consider renal function, as impaired clearance may affect tracer distribution. - Pregnant or breastfeeding patients should be evaluated carefully due to unknown fetal exposure. - Document and monitor vital signs during and after administration.

Glucopet may interact with other agents that influence glucose metabolism or radiation exposure.

Avoid: - Concurrent administration of high‑dose glucose or insulin that could alter tracer uptake. - Use of other radiopharmaceuticals within a short interval that may cause cumulative radiation dose.

Use with caution: - Medications that affect blood glucose levels, such as oral hypoglycemics. - Contrast agents used in CT imaging performed shortly before or after PET. - Drugs that modify cellular metabolism, including certain chemotherapeutic agents.